Know Cancer

forgot password

Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Phase 2
18 Years
Open (Enrolling)
Adrenocortical Carcinoma

Thank you

Trial Information

Phase II Clinical Trial of Dovitinib (TKI-258) in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma

Non applicable

Inclusion Criteria:

- Male or female patients aged ≥ 18 years old

- A performance status of 0, 1, or 2, according to the Eastern Cooperative Oncology
Group (ECOG) scale.

- Histologically confirmed adrenocortical carcinoma.

- Metastatic or locally advanced non-resectable disease.

- At least one radiologically measurable lesion, according to RECIST 1.1.

- Adequate liver function as shown by: serum or plasma ALT and AST ≤ 3.0 x ULN
(regardless of the presence or absence of metastases)and serum or plasma total
bilirubin: ≤ 1.5 x ULN.

- Adequate bone marrow function as shown by: blood absolute neutrophil count (ANC) ≥
1.5 x 109/L, platelets ≥ 100 x 109/L and hemoglobin (Hb) > 9g/dL.

- Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN.

- Patients give a written informed consent obtained according to local guidelines.

Exclusion Criteria:

- Prior chemotherapy other than mitotane (Patients who have previously received
mitotane will only be eligible if drig has been withdrawn at least two weeks earlier
than dovitinib first dose is administered).

- Patients with another primary malignancy within 3 years prior to starting the study
drug, with the exception of adequately treated in-situ carcinoma of the uterine
cervix, or completely excised basal or squamous cell carcinoma of the skin.

- Patients who have received radical radiotherapy ≤4 weeks prior to starting the study
treatment or who have not recovered from radiotherapy-related toxicities. Palliative
radiotherapy for bone lesions ≤2 weeks prior to starting study treatment is allowed.

- Patients who have undergone any major surgery (i.e., intra-thoracic, intrabdominal,
or intra-pelvic) ≤4 weeks prior to starting study treatment or who have not recovered
from side effects of such therapy.

- Patients with a history of pulmonary embolism (PE) within the past 6 months or
untreated deep-venous-thrombosis (DVT) within the past 6 months. Adequately treated
DVT will be permitted providing that patient has been on anticoagulation for at least
2 weeks.

- Patients with impaired cardiac function or clinically significant cardiac diseases,
including any of the following:

- History or presence of serious uncontrolled ventricular arrhythmias.

- Clinically significant resting bradycardia.

- LVEF <45% when assessed by 2-D echocardiogram (ECHO) or multiple gated
acquisition scan (MUGA). (No basal cardiac test is mandatory other than ECG)

- Any of the following within 6 months prior to starting study treatment:
Myocardial infarction (MI), severe/unstable angina, Coronary Artery Bypass Graft
(CABG), Congestive Heart Failure (CHF),Cerebrovascular Accident (CVA), Transient
Ischemic Attack TIA).

- Uncontrolled hypertension defined by a SBP ≥160 mm Hg and/or DBP ≥100 mm Hg,
with or without anti-hypertensive medication. Initiation or adjustment of
antihypertensive medication (s) is allowed prior to study entry.

- Patients with impairment of gastrointestinal (GI) function or GI disease that may
significantly alter the absorption of Dovitinib (TKI258) (i.e., severe ulcerative
diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or
extensive (>1m) small bowel resection, inability to swallow oral medications). Prior
partial or total gastrectomy is not an exclusion criterion.

- Known diagnosis of human immunodeficiency virus (HIV) infection. HIV testing is not

- Patients who are currently receiving full dose of anticoagulation treatment with
therapeutic doses of dicumarinical drugs as warfarin/acenocoumarol or anti-platelet
therapy (i.e.,clopidogrel bisulfate). Treatment with acetylsalicyclic acid 100mg
daily is allowed, as well as prophylactic or therapeutic low-weight-heparin.

- Pregnant or breast-feeding women.

- Women of child-bearing potential not employing an effective method of birth control.
Effective contraception (e.g. condom with spermicidal jelly, foam suppository or
film; diaphragm with spermicide; male condom and diaphragm with spermicide) must be
used throughout the trial and 8 weeks after the end of Dovitinib treatment. Oral,
implantable, or injectable contraceptives may be affected by cytochrome P450
interactions, and are therefore not considered effective for this study. Women of
child-bearing potential defined as sexually mature women who have not undergone a
hysterectomy or who have not been naturally postmenopausal for at least 12
consecutive months (i.e., who has had menses any time in the preceding 12 consecutive
months), must have a negative serum pregnancy test ≤ 14 days prior to starting study
drug. Women of child-bearing potential not employing and not willing to use an
effective method of birth control. Post-menopausal women must have been amenorrheic
for at least 12 months to be considered of non-childbearing potential.

- Fertile males not willing to use contraception as stated above.

- Patients unwilling or unable to comply with the protocol.

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Efficacy in terms of overall response rate (ORR) of dovitinib as treatment for metastatic or locally advanced non-resectable primary adrenocortical carcinoma (measured by an external evaluator)

Outcome Time Frame:

Up to 6 months (Study treatment expected duration)

Safety Issue:


Principal Investigator

Jesús García-Donás Jiménez, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Spanish Oncology Genito-Urinary Group


Spain: Agencia Española de Medicamentos y Productos Sanitarios

Study ID:




Start Date:

January 2012

Completion Date:

January 2014

Related Keywords:

  • Adrenocortical Carcinoma
  • Adrenocortical carcinoma
  • Carcinoma
  • Adrenocortical Carcinoma